Biosyntech Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Biosyntech prevailing Real Value cannot be determined due to lack of data. The current price of Biosyntech is $0.0. Our model approximates the value of Biosyntech from analyzing the firm fundamentals such as Price To Earning of (0.01) X, current valuation of 116.44 K, and Return On Asset of -0.52 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Biosyntech's price fluctuation is out of control at this time. Calculation of the real value of Biosyntech is based on 3 months time horizon. Increasing Biosyntech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biosyntech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biosyntech Pink Sheet. However, Biosyntech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 | Naive 3.0E-6 |
The intrinsic value of Biosyntech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Biosyntech's stock price.
Estimating the potential upside or downside of Biosyntech helps investors to forecast how Biosyntech pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biosyntech more accurately as focusing exclusively on Biosyntech's fundamentals will not take into account other important factors: Biosyntech Total Value Analysis
Biosyntech is currently anticipated to have valuation of 116.44 K with market capitalization of 116, debt of 0, and cash on hands of 1.44 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biosyntech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
116.44 K | 116 | 0 | 1.44 M |
Biosyntech Investor Information
The company recorded a loss per share of 0.1. Biosyntech had not issued any dividends in recent years. The entity had 19:4 split on the 10th of January 2000. Biosyntech is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Biosyntech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biosyntech has an asset utilization ratio of 0.57 percent. This signifies that the Company is making $0.005662 for each dollar of assets. An increasing asset utilization means that Biosyntech is more efficient with each dollar of assets it utilizes for everyday operations.Biosyntech Profitability Analysis
The company reported the previous year's revenue of 5.06 K. Net Loss for the year was (12.94 M) with profit before overhead, payroll, taxes, and interest of 24.8 K.About Biosyntech Valuation
An absolute valuation paradigm, as applied to Biosyntech Pink Sheet, attempts to find the value of Biosyntech based on its fundamental and basic technical indicators. By analyzing Biosyntech's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Biosyntech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biosyntech. We calculate exposure to Biosyntech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biosyntech's related companies.BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. BIOSYNTECH INC is traded on PNK Exchange in the United States.
8 Steps to conduct Biosyntech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biosyntech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biosyntech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biosyntech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biosyntech's revenue streams: Identify Biosyntech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biosyntech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biosyntech's growth potential: Evaluate Biosyntech's management, business model, and growth potential.
- Determine Biosyntech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biosyntech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Biosyntech Pink Sheet
If you are still planning to invest in Biosyntech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biosyntech's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges |